Similar articles

• Carnitine, valproate, and toxicity.

  Coulter DL. Coulter DL. J Child Neurol. 1991 Jan;6(1):7-14. doi: 10.1177/088307389100600102. J Child Neurol. 1991. PMID: 2002205 Review.
• Valproate-induced hepatoxicity: protective effect of L-carnitine supplementation.

  Sugimoto T, Nishida N, Murakami K, Woo M, Sakane Y, Yasuhara A, Shuto H, Hatanaka T, Kobayashi Y. Sugimoto T, et al. Jpn J Psychiatry Neurol. 1990 Jun;44(2):387-8. Jpn J Psychiatry Neurol. 1990. PMID: 2124297 No abstract available.
• [Acute fatal liver insufficiency due to valproic acid therapy].

  Binek J, Hany A, Egloff B, Heer M. Binek J, et al. Schweiz Med Wochenschr. 1991 Feb 16;121(7):228-33. Schweiz Med Wochenschr. 1991. PMID: 2008603 Review. German.
• [Laboratory parameters in valproate therapy].

  Schneble H. Schneble H. Nervenarzt. 1982 Dec;53(12):684-90. Nervenarzt. 1982. PMID: 6818481 German. No abstract available.
• A suspected case of late-onset sodium-valproate-induced hepatic failure.

  van Egmond H, Degomme P, de Simpel H, Dierick AM, Roels H. van Egmond H, et al. Neuropediatrics. 1987 May;18(2):96-8. doi: 10.1055/s-2008-1052461. Neuropediatrics. 1987. PMID: 3110642